Joshua Pinto - 13 Nov 2025 Form 4 Insider Report for Metsera, Inc. (MTSR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Nov 2025, 21:00:13 UTC
Prior SEC filing
30 May 2025
Next SEC filing
09 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Matthew Lang, Attorney-in-Fact for Joshua Pinto

Key filing fact

Joshua Pinto filed Form 4 for Metsera, Inc. (MTSR) on 13 Nov 2025.

Key facts

  • This page summarizes Joshua Pinto's Form 4 filing for Metsera, Inc. (MTSR).
  • 4 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 13 Nov 2025, 21:00.

Change

  • Previous filing in this sequence was filed on 30 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001992595 Primary reporting owner

Pinto Joshua

Relationship
Director
Address
C/O METSERA, INC. 3 WORLD TRADE, CENTER 175 GREENWICH STREET, NEW YORK
Signature
/s/ Matthew Lang, Attorney-in-Fact for Joshua Pinto
Signature date
13 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MTSR transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-2,688
Change %
-100%
Price
Shares after
0
Date
13 Nov 2025
Ownership
Direct
Footnotes
F1, F2, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTSR transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares
+2,688
Change %
Price
Shares after
2,688
Date
13 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,688
Exercise price
$0.000000
Footnotes
F5
MTSR transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-16,125
Change %
-100%
Price
Shares after
0
Date
13 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
16,125
Exercise price
$29.25
Footnotes
F3, F4, F6
MTSR transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-148,953
Change %
-100%
Price
Shares after
0
Date
13 Nov 2025
Ownership
By LLC
Underlying class
Common Stock
Underlying amount
148,953
Exercise price
$4.33
Footnotes
F3, F4, F7, F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Joshua Pinto is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 8 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash,

Footnote F2

(Continued from footnote 1) without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

Footnote F3

Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options,

Footnote F4

(Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

Footnote F5

On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting.

Footnote F6

This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025.

Footnote F7

This option provided for vesting in 36 substantially equal monthly installments from September 27, 2024.

Footnote F8

Reflects securities held by Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .